Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
Executive Summary
First four 351(k) BLA approvals highlight emerging FDA positions on issues from naming to the role of biosimilar-specific data, as detailed in Pink Sheet's Drug Review Profile series.
You may also be interested in...
Mylan, Amgen Biosimilars Sail Through Advisory Panels, May Diverge From There
Mylan's Herceptin biosimilar faces questions on off-label use and manufacturing, while Amgen's Avastin biosimilar could be template for other products.
US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement
Four of first 10 publicly disclosed applications were approved on first review cycle, and FDA has issued at least seven complete response letters. Increasing first-cycle approvals is a primary goal of the BsUFA II agreement.
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
Infliximab-abda gains FDA licensure without having faced an advisory committee review; under current case law, launch could come as early as mid-October.